Merck

- One-Year Data Showed Investigational Use of Initial Combination Therapy with JANUVIA™ (sitagliptin) and Metformin Significantly Improved Blood Sugar Control in Patients with Type 2 Diabetes Compared to Metformin Alone
- Data Also Showed that Initial Combination Therapy with JANUVIA and Metformin Led to Significant Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

First Time State and City Bring Joint Action to Fight Medicaid Fraud; Suit Claims Merck & Co. Endangered Patients, Cost Medicaid Millions

September 17, 2007 -- New York City Mayor Michael R. Bloomberg and New York State Attorney General Andrew M. Cuomo today filed a joint lawsuit against the maker of Vioxx for misrepresenting the dangers the drug posed to its users.    » read more »

FirstTime State and City Bring Joint Action to Fight Medicaid Fraud; Suit claims Merck & Co. endangered patients, cost Medicaid millions

NEW YORK, NY (September 17, 2007) – New York Attorney General Andrew M. Cuomo and New York City Mayor Michael Bloomberg today filed a joint lawsuit against the maker of Vioxx for misrepresenting the dangers the drug posed to its users.    » read more »

Homegrown company becomes global leader

May 13, 2007 -- Pharmaceutical makers Mylan Laboratories Inc. and Merck KGaA on Saturday announced the signing of a definitive agreement under which Mylan will acquire Merck’s generics business for $6.7 billion, making Mylan the world’s third-largest manufacturer of generic drugs.    » read more »

04 May 2007 -- Brazil has rejected a U.S. drug maker's offer of a 30 percent discount on an anti-AIDS drug, Efavirenz.

President Luiz Inacio Lula da Silva's office is now deciding whether to break the drug's patent by making it or buying generic versions.

A spokesperson from Merck expressed disappointment at Brazil's rejection of the offer and said Merck had repeatedly asked to meet with Brazil's Health Ministry to reach an agreement.    » read more »